Tuberous sclerosis complex
Abstract
Tuberous sclerosis complex is a genetic disorder with a characteristic development of a benign tumorous growth in various tissues. Clinical picture is very heterogeneous, resulting in difficult diagnosis and unrecognized patients. In this article, we present pathophysiological basis for understanding the clinical picture and the diagnosis of tuberous sclerosis complex. The skin, central nervous system, kidneys and heart are the most commonly affected sites. The disease course is progressive. Although the great majority of lesions are benign, life expectancy and quality of life are affected by their secondary impact. Until recently, the therapy has been only symptomatic, but nowadays the inhibitors of mTOR complex, such as everolimus, are efficient in reducing the growth of tumors.
Downloads
References
Bruce R. Korf M. The phakomatoses. Clin. Dermatol. 2005; 23: 78–84.
Schwartz RA, Fernández G, Kotulska K, Jóźwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J. Am. Acad. Dermatol. 2007; 57: 189–202.
Moolten SE. Hamartial nature of the tuberous sclerosis complex and its bearing on the tumor problem. Report of a case with tumor anomaly of the kidney and adenoma sebaceum. Arch. Intern. Med. 1942; 69: 589.
Osborne, J P. Fryer, A. Webb D. Epidemiology of tuberous sclerosis. Ann. N. Y. Acad. Sci. 1991; 615: 125–7.
Callaghan FJKO, Shiell AW, Osborne JP. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998; 351: 1998.
Yates JRW, Maclean C, Higgins JNP, Humphrey A, le Maréchal K, Clifford M, et al. The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management. Arch. Dis. Child. 2011 96: 1020–5.
Budde K, Gaedeke J. Tuberous sclerosis complex--associated angiomyolipomas: focus on mTOR inhibition. Am. J. kidney Dis. Off. J. Natl. Kidney Found 2012; 59: 276–83.
Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372: 657–68. 9. Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000; 19: 6306–16.
Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N. Engl. J. Med. 2006; 355: 1345–56.
Camposano SE, Greenberg E, Kwiatkowski DJ, Thiele EA. Distinct clinical characteristics of Tuberous Sclerosis Complex patients with no mutation identified. Ann. Hum. Genet. 2009; 73: 141–6.
Devlin LA, Shepherd CH, Crawford H, Morrison PJ. Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland. Dev. Med. Child Neurol. 2006 48: 495–9.
Narod S a, Stiller C, Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br. J. Cancer 1991; 63: 993–9.
Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J. Child Neurol. 1998; 13: 624–8.
BF W. The electroencephalogram in tuberous sclerosis. In: Gomez MR, Sampson JR WV, editor. Tuberous Scler. Complex Dev. Perspect. Psychiatry. 3rd ed. New York: Oxford University Press; 1999. p. 63.
Prather P, De Vries PJ. Behavioral and cognitive aspects of tuberous sclerosis complex. J. Child Neurol 2004; 19: 666–74.
De Vries PJ, Hunt A, Bolton PF. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur. Child Adolesc. Psychiatry. 2007; 16: 16–24.
Rakowski SK, Winterkorn EB, Paul E, Steele DJR, Halpern EF, Thiele E a. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int. 2006; 70: 1777–82.
Jóźwiak S, Kotulska K, Kasprzyk-Obara J, Domańska-Pakieła D, Tomyn-Drabik M, Roberts P, et al. Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Pediatrics. 2006 ; 118: e1146–51.
Roach ES, Sparagana SP. Diagnosis of Tuberous Sclerosis Complex. J. Child Neurol 2004; 19: 643–9.
Rowley SA. Ophthalmic manifestations of tuberous sclerosis: a population based study. Br. J. Ophthalmol. 2001; 85: 420–3.
Jóźwiak S, Pedich M, Rajszys P, Michalowicz R. Incidence of hepatic hamartomas in tuberous sclerosis. Arch. Dis. Child 1992; 67: 1363–5.
Mlynarczyk G. Enamel pitting: a common symptom of tuberous sclerosis. Oral Surg. Oral Med. Oral Pathol. 1991 71: 63–7.
Lygidakis NA, Lindenbaum RH. Pitted enamel hypoplasia in tuberous sclerosis patients and first--degree relatives. Clin. Genet. 1987 ; 32: 216–21.
Northrup H, Krueger D a. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr. Neurol. 2013 ; 49: 243–54.
Shepherd, C W. Gomez, M R. Lie, J T. Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin. Proc. 1991; 66: 792–6.
Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51: 1236–41.
Beaumont TL, Limbrick DD, Smyth MD. Advances in the management of subependymal giant cell astrocytoma. Childs. Nerv. Syst. 2012 ; 28: 963–8.
Al-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 1998; 83: 2208–16.
Clarke A, Hancock E, Kingswood C, Osborne JP. Nephrology Dialysis Transplantation End-stage renal failure in adults with the tuberous sclerosis complex. 1999; 988–91.
Luna CM, Gené R, Jolly EC, Nahmod N, Defranchi HA, Patiño G, et al. Pulmonary lymphangiomyomatosis associated with tuberous sclerosis. Treatment with tamoxifen and tetracycline-pleurodesis. Chest 1985; 88: 473–5.
Machuca TN, Losso MJ, Camargo SM, Schio SM, Melo IA, Hochhegger B, et al. Lung transplantation for lymphangioleiomyomatosis: single-center Brazilian experience with no chylothorax. Transplant. Proc 2014; 43: 236–8.
Papadavid E, Markey A, Bellaney G, Walker NPJ. Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis. Br. J. Dermatol 2002 147: 337–42.
Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin. Cancer Res. 2011 ; 17: 4071–81.
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo--controlled phase 3 trial. Lancet 2013; 381: 125–32.
Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 817–24.
GmbH NP. Votubia 2,5 mg tbl. p. 1–91.
Wienecke R, Fackler I, Linsenmaier U, Mayer K, Licht T, Kretzler M. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am. J. Kidney Dis 2006; 48: e27–9.
Sooriakumaran P, Anderson CJ. Everolimus for renal angiomyolipoma in tuberous sclerosis. Lancet 2013; 6736: 783–5.
Krueger D a, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr. Neurol 2013; 49: 255–65.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
